AI Article Synopsis
- The immune system protects the body by eliminating harmful elements, but tumors can develop even in patients with a functioning immune system, indicating an imbalance that allows tumor cells to thrive.
- The text explores various strategies to enhance the immune response against tumors, emphasizing the importance of how tumor antigens are presented and recognized by the immune system.
- It also examines non-HLA-restricted immunity, which involves immune cells like natural killer cells that can respond to threats without needing to recognize specific antigens.
Article Abstract
The immune system is a complex arrangement of cellular interactions that preserve the integrity of a organism by elimination of all elements judged dangerous. However, the development of tumours in immunocompetent patients suggests the existence of an imbalance that favours tumour cells against the immune response. What are the different possibilities for reversing this process to drive an efficient antitumour response? We discuss, focusing on the haematological features, classic immunity (ie, antigen-specific and HLA-restricted immunity). We address the central issues of tumour antigen presentation and recognition and their possible clinical use. Last, we discuss non-HLA-restricted immunity, which does not require the recognition of specific antigens and relies on particular cell populations such as natural killer cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1470-2045(03)01323-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies.
Cell
December 2024
Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA; Center for RNA Biology and Therapeutics, City of Hope Beckman Research Institute, Duarte, CA 91010, USA. Electronic address:
Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth relies on efficient ATP synthesis, although the underlying mechanisms remain unclear. Here, we report that YTHDF2 facilitates energy supply and antigen escape in B cell malignancies, and its overexpression alone is sufficient to cause B cell transformation and tumorigenesis.
View Article and Find Full Text PDFMalignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome.
Leuk Lymphoma
December 2024
Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by uncontrolled immune activation. While traditionally associated with genetic mutations affecting cytotoxic function, recent advances have highlighted the prevalence and significance of HLH in adults, particularly in hematologic malignancies. This review focuses on malignancy-associated HLH (M-HLH), a complex and challenging condition with a poor prognosis.
View Article and Find Full Text PDFSecond Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review.
JAMA Oncol
December 2024
Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.
Importance: The commercialization of chimeric antigen receptor-T-cell (CAR-T) therapy has changed the landscape of treatment of hematological cancers. Numerous studies from the early 2000s paved the way for cell-based targeted therapeutics, which have been established as practice-changing therapies in lymphoma, leukemia, and multiple myeloma. However, there has been some recent concern about the risk for second primary cancers (SPCs).
View Article and Find Full Text PDFBiology of post-transplant relapse: actionable features.
Hematology Am Soc Hematol Educ Program
December 2024
Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy.
In patients receiving allogeneic hematopoietic cell transplantation to cure acute myeloid leukemia (AML), recurrence of the underlying disease, or relapse, represents a crucial unanswered issue and prominent cause of mortality. Still, over recent years, advancements in omic technologies have allowed us to gain new insights into the dynamic changes occurring in cancer and the host over the course of treatments, providing a novel evolutionary perspective on the issue of disease relapse. In this review, we summarize current knowledge on the molecular features of relapsing AML, with a specific focus on changes in the mutational asset of the disease and in the interplay between the tumor and the donor-derived immune system.
View Article and Find Full Text PDFReduced GATA1 levels are associated with ineffective erythropoiesis in sickle cell anemia.
Haematologica
December 2024
Red Cell Haematology Lab, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London.
Ineffective erythropoiesis (IE) is defined as the abnormal differentiation and excessive destruction of erythroblasts in the marrow, accompanied by an expanded progenitor compartment and relative reduction in the production of reticulocytes. It is a defining feature of many types of anemia, including beta-thalassemia. GATA1 is an essential transcription factor for erythroid differentiation, known to be implicated in hematological conditions presenting with IE, including beta-thalassemia and congenital dyserythropoietic anemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!